Introduction
============

Trigeminal neuralgia is a severe unilateral facial pain involving one or more branches of the trigeminal nerve ([@b1-etm-0-0-8871],[@b2-etm-0-0-8871]). It is usually unilateral, severe, transient, and recurrent, causing great pain to patients. As the disease progresses, patients may have difficulty eating, talking and maintaining facial hygiene in fear of triggering the pain, which has a profound impact on the quality of life ([@b1-etm-0-0-8871],[@b3-etm-0-0-8871],[@b4-etm-0-0-8871]). Neuropathic pain is common in trigeminal neuralgia, peripheral neuropathy, and multiple sclerosis ([@b5-etm-0-0-8871]). Primary trigeminal neuralgia is caused by the compression of the trigeminal nerve by adjacent blood vessels ([@b6-etm-0-0-8871]), which is recurrent and very difficult to treat conservatively. Its unbearable severe pain has serious effects on the physical and psychological health of patients ([@b7-etm-0-0-8871]), so its treatment has become the focus of clinical research.

The current preferred surgical treatment for primary trigeminal neuralgia is microvascular decompression (MVD) ([@b10-etm-0-0-8871]). MVD, a minimally invasive interventional technique which is able to identify the pain nerve, can effectively isolate the responsible vessels compressing the roots of the trigeminal nerve and the brainstem so as to relieve the compression, and repair the pain nerve under the operating microscope to eradicate the trigeminal pain source. This minimally invasive technique completely retains the function of blood vessels and nerves, is an effective treatment for trigeminal neuralgia ([@b11-etm-0-0-8871],[@b12-etm-0-0-8871]). However, clinical data revealed that MVD is not effective for some patients, leaving poorly relieved pain and a large postoperative trauma ([@b13-etm-0-0-8871]). Percutaneous stereotactic radiofrequency rhizotomyroot (PSR) is also common in treating primary trigeminal neuralgia ([@b14-etm-0-0-8871]), suitable for cases like recurrent disease after surgery and failed identification of the responsible blood vessels by MVD. PSR only partially cuts off the sensory roots, so it can save the function of the patient\'s movement roots and relieve the patient\'s facial pain in a very effective manner ([@b15-etm-0-0-8871]). However, clinical records show that some patients treated with PSR are prone to a variety of complications and a poor prognosis ([@b16-etm-0-0-8871]).

To find a better treatment for primary trigeminal neuralgia, in this study, the clinical efficacy of MVD and MVD combined with PSR in primary trigeminal neuralgia was compared to confirm the effect of MVD and PSR on primary trigeminal neuralgia to provide reference for the treatment of this disease.

Patients and methods
====================

### General information

A prospective analysis was performed. A total of 141 patients with primary trigeminal neuralgia admitted into Shandong Provincial Hospital (Jinan, China) from May 2011 to June 2013 were collected. Among them, 63 patients (26 male and 37 female, aged 37.6±7.9 years) with MVD were studied as group A, while the other 78 (45 male and 33 female, aged 36.5±8.3 years) with MVD combined with PSR were studied as group B.

### Inclusion and exclusion criteria

Inclusion criteria: Patients diagnosed with primary trigeminal neuralgia according to the criteria of the International Headache Society (IHS); patients with no neurological deficits; patients with poor efficacy from drug treatment; patients with significant nerve compression; patient with vascular compression according to imaging examination. The present study was approved by the Ethics Committee of Shandong Provincial Hospital (SPH201104). All patients and their families signed the informed consent.

Exclusion criteria: Patients with cardiovascular and cerebrovascular diseases, malignant tumors, mental disorders, symptoms of secondary trigeminal neuralgia such as multiple sclerosis or tumor nerve compression symptoms; patients with surgery contraindications; pregnant or lactating women.

### Treatment methods

All surgery procedures were performed by the same physician. Patients were generally anesthetized and placed in the prone position, with head down at approximately 15 degrees to expose the mastoid of the operating side at the highest level of the head. In the longitudinal incision in the hairline behind the ear, the retrosigmoid sinus approach was made to fully expose the posterior margin of the mastoid. A hole was drilled in the posterior occipital lacunae of the mastoid and was expanded by a rongeur to make a bone window of approximately 1.5 to 2.5 cm and the transverse sinus and sigmoid sinus were exposed. The mastoid air cell was closed by bone wax. The dura mater was given a '⊥' cut and suspended. The subarachnoid space was opened under the microscope, and the cerebellar hemisphere was lightly pulled to the inner side with the brain plate. The arachnoid was sharply cut with a micro-scissor to identify the compressing vessels and isolate it from the initial segment of the trigeminal nerve root. The Teflon cotton was placed between the responsible vessels and the brain stem to decompress the blood vessels. 6 hours after the completion of MVD, PSR was performed to detect the presence of thick veins on the surgical site to compress the trigeminal nerve. The arachnoid band between the vein and the nerve or the brainstem was cut, and the veins were free. Isolation, distance or suspension were selected to decompress according to the type of venous compression (electrocoagulation shearing can be performed in the case of difficult separation), and then PSR is performed on the sensory nerves 1/3 to 1/5 of the posterior lateral of the trigeminal sensory root. Under the microscope, the trigeminal nerve root was carefully and sharply cut off. The operation is performed with caution. It is strictly required to avoid mechanical damage to blood vessels and nerves.

### Postoperative treatment

The patient was treated with intravenous dexamethasone to avoid postoperative rejection. Routine examinations were performed after the surgery to monitor the recovery and the complications. If no abnormalities were observed, patients were allowed to discharge one week after the surgery.

### Outcome measures

Main outcome measure: The postoperative surgical outcomes of the two groups were observed. The efficacy criteria are shown in [Table I](#tI-etm-0-0-8871){ref-type="table"}.

Secondary outcome measures: The incidence of postoperative complication in the two groups was observed; the risk factors affecting the efficacy were explored by the multivariate analysis; the quality of life after the treatment of the two groups was monitored; the 5-year recurrence rate of the two groups was observed.

### Statistical methods

Statistical analysis was performed using SPSS 19.0 (Chicago SPSS Co., Ltd.), and the collected data were visualized using GraphPad Prism 7 (San Diego Graphpad Software Co., Ltd.). The count data were expressed with rate (%) and compared by the Chi-square test. The measurement data were expressed with the mean ± standard deviation (mean ± SD) and compared between two groups by the independent sample t-test. Logistic regression test was used for multivariate analysis. K-M survival curve was used to analyze the 5-year recurrence of patients. A statistical difference was recognized at P\<0.05.

Results
=======

### General clinical data of group A and group B

Group A (patients treated with MVD) and group B (patients treated with MVD combined with PSR) were not statistically different in age, sex, BMI (kg/m^2^), painful side, clinical symptoms, compressing vessels, compression degree, duration of disease, place of residence, smoking or drinking (P\>0.05). Details are shown in [Table II](#tII-etm-0-0-8871){ref-type="table"}.

### Evaluation of the efficacy in group A and group B

The total effective rate was 88.89% in group A, lower than that in group B (96.15%), but the difference was not statistically significant (P\>0.05) ([Table III](#tIII-etm-0-0-8871){ref-type="table"}).

### The incidence of complications after treatment in group A and group B

The number of patients experiencing nausea and vomiting, peripheral facial paralysis, hearing loss, cerebrospinal fluid leakage, subcutaneous effusion in group A were 13, 5, 3, 1, and 3, respectively, and the total incidence of adverse reaction in group A was 39.68%, while the numbers in group B were 5, 3, 1, 0, and 1, respectively, and the total incidence of adverse reaction in group B was 12.82%. The difference between the two groups in the adverse reactions was statistically significant (P\<0.05). Additional details are shown in [Table IV](#tIV-etm-0-0-8871){ref-type="table"}.

### Univariate analysis of the efficacy

The two groups of patients were divided into the cured group (n=86) and the not-cured group (n=55) according to efficacy. The univariate analysis of the clinical data of the two groups demonstrated that the cured group and the not-cured group were not statistically different in sex, age, BMI (kg/m^2^), painful side, compressing vessels, smoking, drinking, and place of residence (P\>0.05), but statistically different in the decompression degree, duration of disease, compression degree, and clinical symptoms (P\<0.05). Additional details are shown in [Tables V-VII](#tV-etm-0-0-8871 tVI-etm-0-0-8871 tVII-etm-0-0-8871){ref-type="table"}.

### Comparison of postoperative quality of life between group A and group B

The quality of life of patients at one year of treatment in group B was significantly better than that of patients in group B in terms of physiological role, overall health, physiological function, vitality, physical pain, mental health, emotional function, social function (P\<0.05). More details are shown in [Table VIII](#tVIII-etm-0-0-8871){ref-type="table"}.

### The 5-year recurrence rate in both groups

According to the statistics, all 141 patients and their families were successfully followed up. Five years after the surgery, 18 patients in group A had recurrent disease, with a recurrence rate of 28.57%, and 10 patients in group B had recurrent disease, with a recurrence rate of 12.82%. The figure of the 5-year recurrence of the two groups displayed that the 5-year recurrence rate of group B was statistically lower than that of group A (P=0.022) ([Fig. 1](#f1-etm-0-0-8871){ref-type="fig"}).

Discussion
==========

Primary trigeminal neuralgia is debilitating, characterized by unilateral facial pain following the sensory distribution of cranial nerve V ([@b17-etm-0-0-8871]). Most patients with long-term use of drugs can develop drug resistance and experience side effects ([@b18-etm-0-0-8871]), and thus need surgery. MVD is the most common surgery for primary trigeminal neuralgia, but it is limited by age, pain level, medical comorbidities, past surgery procedures, and patient preference ([@b19-etm-0-0-8871],[@b20-etm-0-0-8871]). Minimally invasive techniques such as PSR are designed to damage nerves for pain control ([@b21-etm-0-0-8871],[@b22-etm-0-0-8871]). To discover better treatments for primary trigeminal nerves, the application of MVD combined with PSR was investigated in this study.

This study found that MVD combined with PSR treatment had better efficacy than MVD alone. The study by Zeng *et al* ([@b23-etm-0-0-8871]) compared the efficacy of MVD combined with PSR and MVD for primary trigeminal neuralgia and found that MVD combined with PSR was better than MVD alone because the pain was completely eliminated soon after PSR combined with MVD, which is similar to the results of the present study. The study by Zeng *et al* only listed the pain relief rate of the patient for two years, but in this study, the follow-up time was extended and it was found that the recurrence rate of patients receiving MVD combined with PSR was significantly lower than that of patients receiving MVD alone. It was speculated that MVD combined with PSR can identify responsible blood vessels more accurately, treat patients with different symptoms and eliminate the pain more efficiently. The study by Du *et al* ([@b24-etm-0-0-8871]) employed percutaneous balloon compression of trigeminal ganglion for recurrent trigeminal neuralgia after MVD because they believed MVD does not achieve a 100% cure rate and it carries high risk and low success rate for recurrent MVD, suggesting that MVD treatment is not suitable for all the patients. MVD is a non-destructive treatment. With identified pain nerve by medical equipment, MVD can relieve the compression of the roots of the trigeminal nerve and preserve the functions of blood vessels and nerves. PSR can remove the root nerve to stop the pain. MVD is not suitable for patients whose responsible vessels are not determined, besides, it causes large trauma. Considering different needs of different patients, it was speculated that MVD combined with PSR treatment can be applied to more patients to achieve better efficacy. The postoperative complications of the two treatments were compared and the results showed that MVD combined with PSR treatment had significantly fewer complications than MVD, indicating that MVD combined with PSR may be a better treatment for primary trigeminal neuralgia. A univariate analysis was performed on the efficacy of the two groups before the multivariate analysis and a statistical difference was found between the patients cured and not cured in the degree of decompression, duration of disease, degree of compression, and clinical symptoms. Multivariate analysis was then performed by logistic regression test and revealed that the decompression degree, duration of the disease, the compression degree, and the clinical symptoms were risk factors for the patient\'s poor efficacy. Such results suggest that more attention should be paid to select suitable treatment for patients with poor decompression and compression degree, long disease duration, and severe clinical symptoms to achieve better efficacy. The following comparison of quality of life scores between the two groups demonstrated that patients treated with MVD combined with PSR had a higher quality of life and a lower 5-year recurrence rate than patients treated with MVD alone. This further suggests that the efficacy of MVD combined with PSR is better.

In summary, MVD combined with PSR in the treatment of primary trigeminal neuralgia has better efficacy, fewer complications, higher quality of life of patients, and lower 5-year recurrence rate than MVD alone. The risk factors affecting the efficacy of patients include the decompression degree, duration of disease, compression degree, and clinical symptoms.
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###### 

Efficacy evaluation.

  Response            Criteria
  ------------------- -------------------------------------------------------------------------------------------------------------------------------------
  Cured               The pain completely disappeared and no drug was needed.
  Marked response     The pain was relieved by 90%, the drug was used occasionally or in a small dose.
  Moderate response   The pain was relieved to a certain degree, the dosage of the drug was reduced by 50%, or the multiple pain turned into single pain.
  No response         The pain was not relieved.

###### 

General clinical data of group A and group B \[n (%)\].

  Factors                       Group A (n=63)   Group B (n=78)   t/χ^2^ value   P-value
  ----------------------------- ---------------- ---------------- -------------- ---------
  Sex                                                             3.760          0.053
       Male                     26 (41.27)       45 (57.69)                       
       Female                   37 (58.73)       33 (42.31)                       
  Age (years)                   37.6±7.9         36.5±8.3         0.799          0.426
  BMI (kg/m^2^)                 23.57±2.15       24.07±2.13       1.380          0.170
  Painful side                                                    0.263          0.608
       Left side                32 (50.79)       43 (55.13)                       
       Right side               31 (49.21)       35 (44.87)                       
  Clinical symptoms                                               0.564          0.453
       Typical                  34 (53.97)       47 (60.26)                       
       Not typical              29 (46.03)       31 (39.74)                       
  Compressing vessels                                             0.983          0.612
       Artery compression       18 (28.57)       17 (21.79)                       
       Venous compression       20 (31.75)       25 (32.05)                       
       Mixed compression        25 (39.68)       36 (46.15)                       
  Compression degree                                              0.017          0.897
       Displaced                30 (44.44)       38 (42.31)                       
       Not displaced            33 (47.62)       40 (46.15)                       
  Duration of disease (years)                                     5.425          0.994
       \<5                      25 (39.68)       31 (39.74)                       
       ≥5                       38 (60.32)       47 (60.26)                       
  Place of residence                                              0.101          0.751
       Urban area               29 (46.03)       38 (48.72)                       
       Rural area               34 (53.97)       40 (51.28)                       
  Smoking                                                         0.015          0.901
       Yes                      26 (41.27)       33 (42.31)                       
       No                       37 (58.73)       45 (57.69)                       
  Drinking                                                        0.726          0.394
       Yes                      23 (36.51)       34 (43.59)                       
       No                       40 (63.49)       44 (56.41)                       

###### 

Evaluation of the efficacy in group A and group B \[n (%)\].

  Response               Group A (n=63)   Group B (n=78)   χ^2^ value   P-value
  ---------------------- ---------------- ---------------- ------------ ---------
  Cured                  38 (60.32)       48 (61.54)       0.022        0.883
  Marked response        10 (15.87)       15 (19.23)       0.269        0.604
  Moderate response      8 (12.70)        12 (15.38)       0.207        0.650
  No response            7 (11.11)        3 (3.85)         2.792        0.095
  Total effective rate   56 (88.89)       75 (96.15)       2.792        0.095

###### 

The incidence of complications after treatment in group A and group B \[n (%)\].

  Group            Nausea and vomiting   Peripheral facial paralysis   Hearing loss   Cerebrospinal fluid leakage   Subcutaneous effusion   Total        χ^2^ value   P-value
  ---------------- --------------------- ----------------------------- -------------- ----------------------------- ----------------------- ------------ ------------ ---------
  Group A (n=63)   13 (20.63)            5 (7.94)                      3 (4.76)       1 (1.59)                      3 (4.76)                25 (39.68)   13.48        \<0.001
  Group B (n=78)   5 (6.41)              3 (3.85)                      1 (1.28)       0 (0)                         1 (1.28)                10 (12.82)                 

###### 

Univariate analysis.

  Factors                       Cured group (n=86)   Not-cured group (n=55)   t/χ^2^ value   P-value
  ----------------------------- -------------------- ------------------------ -------------- ---------
  Sex                                                                         0.010          0.919
       Male                     32 (37.21)           20 (36.36)                               
       Female                   54 (62.79)           35 (63.64)                               
  Age (years)                   39.7±8.1             38.5±8.3                 0.850          0.397
  BMI (kg/m^2^)                 25.87±2.83           26.07±1.78               0.468          0.641
  Painful side                                                                0.066          0.767
       Left side                41 (47.67)           25 (45.45)                               
       Right side               45 (52.33)           30 (54.55)                               
  Clinical symptoms                                                           12.840         \<0.001
       Typical                  62 (72.09)           23 (41.82)                               
       Not typical              24 (27.91)           32 (58.18)                               
  Compressing vessels                                                         4.250          0.119
       Artery compression       27 (31.40)           14 (25.45)                               
       Venous compression       30 (34.88)           13 (23.64)                               
       Mixed compression        29 (33.72)           28 (50.91)                               
  Compression degree                                                          13.600         \<0.001
       Displaced                29 (33.72)           36 (65.45)                               
       Not displaced            57 (66.28)           19 (34.55)                               
  Decompression degree                                                        47.130         \<0.001
       Full decompression       74 (86.05)           16 (29.09)                               
       Not-full decompression   12 (13.95)           39 (70.91)                               
  Duration of disease (years)                                                 16.510         \<0.001
       \<5                      52 (60.47)           14 (25.45)                               
       ≥5                       34 (39.53)           41 (74.55)                               
  Place of residence                                                          0.299          0.585
       Urban area               46 (53.49)           32 (58.18)                               
       Rural area               40 (46.51)           23 (41.82)                               
  Smoking                                                                     1.033          0.309
       Yes                      36 (47.37)           31 (56.36)                               
       No                       50 (52.63)           24 (43.64)                               
  Drinking                                                                    0.211          0.646
       Yes                      33 (38.37)           19 (34.55)                               
       No                       53 (61.63)           36 (65.45)                               

###### 

Assignments.

  Factors                Assignment
  ---------------------- ------------------------------------------------
  Decompression degree   Full decompression=1; not-full decompression=0
  Duration of disease    \<5 years=1; ≥5 years=0
  Compression degree     \>2 times=1; 2 times=0
  Clinical symptoms      Typical=0; not typical=1

###### 

Multivariate analysis for factors affecting efficacy.

                                                                  95% C.I. of EXP (B)   
  ---------------------- ------- ------- -------- ------- ------- --------------------- --------
  Duration of disease    0.889   0.409   4.175    0.030   2.432   1.090                 5.423
  Clinical symptoms      3.132   0.895   2.238    0.000   6.917   3.964                 13.498
  Compression degree     1.172   0.347   11.431   0.001   3.299   1.637                 6.371
  Decompression degree   4.060   1.009   4.208    0.000   7.312   8.034                 14.732

###### 

Comparison of postoperative quality of life between group A and group B.

  Quality of life score    Group B (n=78)                                              Group A (n=63)   t value   P-value
  ------------------------ ----------------------------------------------------------- ---------------- --------- ---------
  Physiological role       36.19±6.61^[a](#tfn1-etm-0-0-8871){ref-type="table-fn"}^    25.53±5.28       8.068     \<0.001
  Overall health           39.62±8.34^[a](#tfn1-etm-0-0-8871){ref-type="table-fn"}^    28.39±8.70       5.967     \<0.001
  Physiological function   42.52±11.09^[a](#tfn1-etm-0-0-8871){ref-type="table-fn"}^   33.65±10.11      3.785     \<0.001
  Vitality                 44.45±6.91^[a](#tfn1-etm-0-0-8871){ref-type="table-fn"}^    35.98±6.67       5.647     \<0.001
  Physical pain            46.94±8.81^[a](#tfn1-etm-0-0-8871){ref-type="table-fn"}^    37.05±8.01       5.318     \<0.001
  Mental health            48.18±7.28^[a](#tfn1-etm-0-0-8871){ref-type="table-fn"}^    36.72±7.23       7.152     \<0.001
  Emotional function       43.42±8.78^[a](#tfn1-etm-0-0-8871){ref-type="table-fn"}^    32.97±8.19       5.573     \<0.001
  Social function          43.72±7.89^[a](#tfn1-etm-0-0-8871){ref-type="table-fn"}^    36.87±7.16       4.117     \<0.001

^a^P\<0.05 when compared with group A after treatment.
